Ophthalmology – Eyelid Neoplasms, Malignant

Malignant eyelid neoplasms can arise from virtually any tissue of the ocular adnexa. Early recognition is critical because these tumors can cause local tissue destruction, orbital invasion, lymphatic or hematogenous spread, visual loss, and potentially death. The major malignant eyelid tumors are basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sebaceous gland carcinoma, and malignant melanoma. Less common malignant lesions include Merkel cell carcinoma, Kaposi sarcoma, cutaneous T-cell lymphoma, and MALT lymphoma.

Approximately 5–10% of all skin cancers involve the eyelid. Basal cell carcinoma is by far the most common malignant eyelid tumor, accounting for approximately 80–90% of cases. Squamous cell carcinoma accounts for roughly 5–10%, sebaceous carcinoma for approximately 1–5%, and malignant melanoma for about 1% or less.

The most important risk factor is chronic ultraviolet exposure. Other risk factors include fair skin, Caucasian ethnicity, advanced age, previous skin cancer, immunosuppression, previous radiation, chronic scars or burns, and arsenic exposure. Preventive measures therefore include limiting excessive sun exposure and using appropriate UV protection, especially from childhood onward.

Pathophysiology

Chronic ultraviolet radiation can cause mutations and defects in DNA repair pathways. When damaged cells escape normal regulatory mechanisms, they may undergo malignant transformation and proliferate uncontrollably.

The biologic behavior varies considerably among tumor types. Some lesions, such as BCC, are usually slow growing and rarely metastasize but can become profoundly locally destructive. Others, particularly sebaceous carcinoma and melanoma, possess substantial metastatic potential.

⸻

Basal Cell Carcinoma

Basal cell carcinoma arises from basal cells of the epidermis. It is the most common malignant eyelid tumor and most frequently involves the lower eyelid, followed by the medial canthus, upper eyelid, and lateral canthus.

BCC generally grows slowly and metastasizes only rarely. However, it can be locally invasive, particularly when located near the medial canthus, where spread into the orbit and adjacent structures may occur before the extent of disease is clinically obvious.

The classic form is a pearly, firm, indurated nodule with surface telangiectatic vessels, sometimes accompanied by central ulceration. Nodulo-ulcerative lesions may produce the characteristic appearance of a central ulcer with raised pearly borders.

The morpheaform or sclerosing subtype is flatter and more infiltrative. It may appear as a firm, pale or yellow-white plaque with indistinct borders and relatively intact overlying epidermis. Because the clinical margins are poorly defined, complete removal can be more difficult.

Superficial multifocal BCC involves a broader area of the epidermis and dermis and may have a more irregular surface.

⸻

Squamous Cell Carcinoma

Squamous cell carcinoma arises from the squamous epithelial layer of the epidermis. Unlike BCC, SCC may develop from premalignant lesions such as actinic keratosis, Bowen disease, or radiation-related skin damage.

The lower eyelid is the most common site, followed by the medial canthus, upper eyelid, and lateral canthus. SCC may present as a painless nodule, plaque, ulcerated lesion, or crusted lesion and can sometimes resemble basal cell carcinoma.

SCC has a greater tendency than BCC to metastasize to regional lymph nodes. Particularly concerning is perineural invasion, because tumor cells can track along nerves into the orbit, intracranial cavity, or surrounding facial structures.

Histologically, invasive SCC demonstrates atypical squamous cells crossing the basement membrane into the dermis, often with keratin pearls and dyskeratotic cells.

⸻

Sebaceous Gland Carcinoma

Sebaceous gland carcinoma most commonly arises from the meibomian glands of the eyelid or the glands of Zeis. It is an especially important tumor because it frequently masquerades as a benign inflammatory disorder.

It may present as a recurrent or persistent chalazion, chronic unilateral blepharitis, or blepharoconjunctivitis. For this reason, it is often called the “great masquerader.”

The upper eyelid is commonly involved because it contains a greater number of meibomian glands.

A key clinical warning sign is loss of eyelashes (madarosis) in the region of the lesion. Sebaceous carcinoma can be multicentric and may spread within the epithelium in a pagetoid pattern, involving areas beyond the clinically visible tumor.

The tumor can spread directly into the orbit, paranasal sinuses, and intracranial structures, and can metastasize through lymphatic pathways to regional lymph nodes and distant organs.

Because recurrence after treatment is possible, long-term surveillance is essential.

⸻

Malignant Melanoma

Malignant melanoma of the eyelid results from malignant proliferation of melanocytes. Although uncommon, melanoma is clinically important because it has significant metastatic potential and is a major cause of death from primary skin tumors.

Major forms include superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma.

Superficial spreading melanoma may appear as an elevated lesion with irregular pigmentation containing combinations of black, brown, tan, rose, gray, or blue.

Nodular melanoma typically forms a raised spherical lesion with a relatively uniform blue-black appearance.

Lentigo maligna melanoma develops from a longstanding pigmented macule that later develops elevation or nodularity.

Tumor thickness is an important prognostic factor. Breslow thickness, which measures the depth of invasion in millimeters, is more clinically important than the older Clark level classification.

Patients require careful systemic assessment because metastatic melanoma can involve regional lymph nodes and distant organs.

⸻

Associated Genetic and Systemic Conditions

Several inherited syndromes substantially increase the risk of malignant eyelid tumors.

Gorlin–Goltz syndrome, or basal cell nevus syndrome, is an autosomal dominant disorder caused by mutations involving the PTCH gene. Patients develop multiple basal cell carcinomas, sometimes beginning in childhood, along with jaw cysts, skeletal abnormalities, and characteristic pits of the palms and soles.

Bazex syndrome is an X-linked dominant disorder associated with early development of multiple facial basal cell carcinomas and characteristic atrophic skin changes.

Xeroderma pigmentosum is an autosomal recessive disorder involving defective DNA repair. Patients develop multiple BCCs, SCCs, and melanomas at unusually young ages because of extreme sensitivity to ultraviolet radiation.

Patients with albinism have decreased protective melanin and therefore have a substantially increased risk of ultraviolet-induced skin malignancies.

⸻

Diagnosis

Any persistent or suspicious eyelid lesion should undergo careful evaluation. Important historical features include duration, rate of growth, previous skin cancer, previous radiation exposure, arsenic exposure, chronic inflammatory disease, and significant UV exposure.

A lesion that repeatedly recurs after treatment as a benign condition deserves particular attention. For example, a “chalazion” that repeatedly returns in the same location should raise concern for sebaceous gland carcinoma.

Physical Examination

The eyelid lesion should be examined carefully for ulceration, abnormal pigmentation, irregular texture, persistent crusting, spontaneous bleeding, and loss of normal eyelid architecture.

Loss of eyelashes, or madarosis, is an especially important sign. Poliosis, or whitening of eyelashes, may also occur.

Abnormal vascularity should be documented. Feeder vessels and telangiectatic vessels at the tumor margins are concerning features.

Signs such as proptosis, diplopia, restricted ocular motility, or external ophthalmoplegia suggest possible orbital invasion and require urgent further evaluation.

Regional lymph nodes, particularly the preauricular, submandibular, and cervical nodes, should be examined for enlargement.

⸻

Biopsy and Histopathology

Histopathologic confirmation is essential for suspected malignant eyelid tumors.

In many lesions, an incisional biopsy can establish the diagnosis before definitive treatment. However, melanoma requires careful biopsy planning because depth of invasion is essential for staging and prognosis.

Basal cell carcinoma typically demonstrates nests of basaloid cells with peripheral palisading.

Squamous cell carcinoma demonstrates atypical squamous cells, often with keratinization and keratin pearls, invading through the basement membrane.

Sebaceous gland carcinoma shows large atypical cells containing foamy lipid-rich cytoplasm, prominent nuclei, and infiltrative growth in lobules, cords, and nests. Pagetoid epithelial spread may also be present.

Melanoma demonstrates atypical melanocytes with abnormal proliferation, loss of normal maturation, and potentially pagetoid upward migration through the epidermis.

⸻

Treatment

Treatment depends on the tumor type, size, location, depth, and extent of spread.

For basal cell carcinoma and squamous cell carcinoma, complete surgical removal with margin control is the standard approach. Techniques include Mohs micrographic surgery or excision with frozen- or permanent-section margin assessment. These approaches provide high cure rates while preserving as much normal eyelid tissue as possible.

For sebaceous gland carcinoma, treatment typically involves complete excision with careful margin control. Because of the possibility of pagetoid spread, conjunctival map biopsies may be required. Additional therapy may be considered when microscopic disease persists. Extensive orbital invasion may necessitate orbital exenteration.

Management of malignant melanoma depends heavily on tumor thickness and stage. Surgical excision with appropriate margins is required, while selected patients may need sentinel lymph node biopsy, lymphatic mapping, and systemic oncologic management.

Radiotherapy may be considered in selected patients when surgery is contraindicated or as an adjunct in particular tumor types.

⸻

Follow-up

Patients generally require close postoperative follow-up initially to ensure adequate wound healing and confirm that no early recurrence is present.

Long-term surveillance is essential. Stable lower-risk tumors may be followed approximately every 6–12 months, while aggressive tumors such as sebaceous carcinoma and melanoma require more frequent and prolonged monitoring.

Patients should also undergo regular full-body skin examinations through a dermatologist or primary care physician because the presence of one skin malignancy increases the likelihood of additional lesions.

Patients with sebaceous carcinoma or melanoma often require coordinated follow-up with medical oncology, while radiation oncology may be involved when radiotherapy is required.

⸻

Patient Education

Patients should be encouraged to minimize ultraviolet exposure by using sunscreen, hats, sunglasses, and other protective measures.

Any new or recurrent eyelid lesion showing growth, ulceration, bleeding, color change, loss of eyelashes, persistent crusting, or alteration of normal eyelid architecture should be evaluated promptly.

Patients previously treated for an eyelid malignancy should understand that long-term surveillance is necessary because recurrence or development of a second skin cancer can occur.

⸻

Prognosis and Complications

The prognosis depends heavily on the specific tumor type, stage at diagnosis, and adequacy of surgical excision.

Early basal cell carcinoma generally has an excellent prognosis when completely removed, whereas advanced SCC, sebaceous carcinoma, and melanoma carry greater risks of regional and systemic spread.

Potential complications include destruction of eyelid anatomy, impaired eyelid function, orbital invasion, intracranial extension, lymphatic or distant metastasis, visual loss, and death.

The most important principle is early recognition and biopsy of suspicious eyelid lesions, because timely diagnosis can prevent extensive local destruction and potentially life-threatening metastatic disease.